Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. ETF
  3. ANIK
ANIK logo

ANIK

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewTechnicalNews
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

ANIK News

Healthcare Stocks Show Overbought Warning Signals

6d agoBenzinga

Anika Therapeutics Q4 2025 Earnings Call Insights

Feb 26 2026seekingalpha

Anika Therapeutics Releases Fiscal 2026 Guidance with Q4 Earnings Beat

Feb 26 2026seekingalpha

Anika Therapeutics to Announce Q4 Earnings on February 26

Feb 25 2026seekingalpha

Anika Therapeutics Faces Investor Lawsuit Over Securities Violations

Jan 26 2026Globenewswire

Anika Therapeutics Shares Plunge 27% After Clinical Trial Fails to Meet Primary Endpoints

Jan 24 2026Businesswire

Anika Therapeutics Shares Plunge 27.42% After Clinical Trial Results Fail to Meet Primary Endpoints

Dec 30 2025Businesswire

Anika Therapeutics Faces Investigation After 27.42% Stock Drop Following Clinical Trial Results

Dec 30 2025Newsfilter

Anika Therapeutics Faces Investigation After Hyalofast Trial Misses Key Endpoints

Dec 06 2025Globenewswire

Anika Therapeutics Faces Investigation After 27.42% Stock Drop Due to Trial Results

Dec 06 2025Newsfilter

Reminder for Anika Investors: Bragar Eagel & Squire, P.C. Urges Anika Therapeutics Shareholders to Reach Out About Ongoing Investigation

Oct 09 2025Globenewswire

Biotech Stocks Recover in After-Hours Trading Driven by Positive Sector Trends

Oct 01 2025NASDAQ.COM

ANIKA (ANIK) UPDATE: Bragar Eagel & Squire, P.C. Launches Investigation into Anika Therapeutics, Inc. for the Benefit of Stockholders and Urges Investors to Reach Out to the Firm

Sep 25 2025Globenewswire

Arcturus Therapeutics (ARCT) Rises 8.7%: Could This Signal More Growth Ahead?

Sep 19 2025NASDAQ.COM

Investor Notice: Pomerantz Law Firm Probes Allegations for Anika Therapeutics, Inc. Shareholders – ANIK

Sep 14 2025Globenewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK

Sep 08 2025PRnewswire